Wall Street brokerages forecast that Alkermes plc (NASDAQ:ALKS) will announce earnings per share (EPS) of $0.09 for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Alkermes’ earnings, with the lowest EPS estimate coming in at $0.07 and the highest estimate coming in at $0.11. Alkermes reported earnings of $0.06 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 50%. The business is scheduled to report its next quarterly earnings results on Wednesday, August 4th.
On average, analysts expect that Alkermes will report full-year earnings of $0.43 per share for the current fiscal year, with EPS estimates ranging from $0.31 to $0.53. For the next fiscal year, analysts anticipate that the business will post earnings of $0.96 per share, with EPS estimates ranging from $0.28 to $1.43. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Alkermes.
Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Tuesday, April 27th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.13. The business had revenue of $251.43 million during the quarter, compared to analyst estimates of $233.78 million. Alkermes had a negative net margin of 6.28% and a positive return on equity of 9.35%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.01 earnings per share.
In related news, CFO Iain Michael Brown sold 34,792 shares of the firm’s stock in a transaction on Monday, April 19th. The stock was sold at an average price of $20.00, for a total value of $695,840.00. Following the completion of the transaction, the chief financial officer now directly owns 48,570 shares of the company’s stock, valued at $971,400. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Wendy L. Dixon sold 25,000 shares of the firm’s stock in a transaction on Monday, April 19th. The stock was sold at an average price of $20.00, for a total value of $500,000.00. Following the completion of the transaction, the director now directly owns 61,600 shares of the company’s stock, valued at $1,232,000. The disclosure for this sale can be found here. Insiders sold 88,920 shares of company stock valued at $1,770,300 over the last three months. 4.49% of the stock is owned by company insiders.
A number of hedge funds have recently modified their holdings of the stock. Virginia Retirement Systems ET AL lifted its position in Alkermes by 109.0% in the first quarter. Virginia Retirement Systems ET AL now owns 139,800 shares of the company’s stock worth $2,611,000 after purchasing an additional 72,900 shares during the period. Meeder Asset Management Inc. raised its stake in Alkermes by 15,286.0% during the first quarter. Meeder Asset Management Inc. now owns 15,386 shares of the company’s stock worth $286,000 after acquiring an additional 15,286 shares in the last quarter. US Bancorp DE raised its stake in Alkermes by 18.2% during the first quarter. US Bancorp DE now owns 4,278 shares of the company’s stock worth $80,000 after acquiring an additional 658 shares in the last quarter. Fisher Asset Management LLC raised its stake in Alkermes by 19.1% during the first quarter. Fisher Asset Management LLC now owns 83,700 shares of the company’s stock worth $1,564,000 after acquiring an additional 13,414 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Alkermes by 1.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 905,900 shares of the company’s stock worth $18,077,000 after acquiring an additional 14,671 shares in the last quarter. 97.30% of the stock is owned by hedge funds and other institutional investors.
Shares of Alkermes stock traded up $0.17 during trading on Tuesday, hitting $22.30. 1,799,236 shares of the stock were exchanged, compared to its average volume of 1,332,691. The stock’s fifty day moving average is $19.98 and its 200 day moving average is $19.73. The stock has a market cap of $3.58 billion, a PE ratio of -48.78, a P/E/G ratio of 12.74 and a beta of 1.25. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.39 and a current ratio of 2.71. Alkermes has a 12 month low of $13.91 and a 12 month high of $23.92.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.